Glaxosmithkline reported $1.24B in Net Income for its third fiscal quarter of 2020.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Net Income Change
Amgen AMGN:US $ 1803M 22M
AstraZeneca AZN:LN 648M 108M
Bristol Myers Squibb BMY:US $ -85M 690M
Corcept Therapeutics CORT:US $ 28M 2M
Eli Lilly And LLY:US $ 1412M 44.5M
Endo International Ordinary Shares ENDP:US $ -75.89M 86.44M
GlaxoSmithKline GSK:LN 2263M 698M
Glaxosmithkline GSK:US $ 1244M 1019M
Gw Pharmaceuticals GWPH:US $ -12.19M 3.36M
Horizon Pharma HZNP:US $ 292.84M 372.85M
JAZZ PHA JAZZ:US $ 148.23M 33.43M
Johnson & Johnson JNJ:US $ 3554M 72M
Merk MRK:US $ 3002M 217M
Pacira Pharmaceuticals PCRX:US $ -7.27M 15.43M
Perrigo Ordinary Shares PRGO:US $ -154.6M 215.2M
Pfizer PFE:US $ 3426M 25M
Takeda 4502:JP Y 4037M 78474M
Valeant Pharmaceuticals VRX:CN $ -326M 174M
Zoetis ZTS:US $ 377M 46M